Systemic risk factors for retinal vein occlusion in young and middle-aged patients
Yu. S. Astakhov,, 
A. I. Titarenko,
S. N. Tultseva,
S. Yu. Astakhov,
Yu. V. Takhtaev,
S. A. Novikov,
V. A. Turgel
A. I. Titarenko,
S. N. Tultseva,
S. Yu. Astakhov,
Yu. V. Takhtaev,
S. A. Novikov,
V. A. Turgel https://doi.org/10.18705/1607-419X-2018-24-6-666-673
Abstract
Retinal vein occlusion (RVO) is an acute vascular retinal disorder, which is associated with local or general endothelial dysfunction. Up to 25 % of RVO cases occur in young and middle-aged patients. The article reviews possible causes of RVO in young and middle-aged subjects. The authors pay attention to independent risk factors for RVO including arterial hypertension, dyslipidemia, diabetes mellitus and acquired and hereditary thrombophilia. Considering a multifactorial origin of RVO, the authors emphasize the need for a multidisciplinary approach in the management of patients with RVO.
About the Authors
Yu. S. Astakhov,
First Pavlov State Medical University of
St. Petersburg.
Russian Federation
Yuriy S. Astakhov, MD, PhD, DSc, Professor, Department of Ophthalmology.
Russian Federation
Yuriy S. Astakhov, MD, PhD, DSc, Professor, Department of Ophthalmology.
A. I. Titarenko
First Pavlov State Medical University of
St. Petersburg.
Russian Federation
Aleksandra I. Titarenko, MD, Post-graduate Student, Department of Ophthalmology.
Russian Federation
Aleksandra I. Titarenko, MD, Post-graduate Student, Department of Ophthalmology.
S. N. Tultseva
First Pavlov State Medical University of
St. Petersburg.
Russian Federation
Svetlana N. Tultseva, MD, PhD, DSc, Professor, Department of Ophthalmology.
Russian Federation
Svetlana N. Tultseva, MD, PhD, DSc, Professor, Department of Ophthalmology.
S. Yu. Astakhov
First Pavlov State Medical University of
St. Petersburg.
Russian Federation
Sergey Yu. Astakhov, MD, PhD, DSc, Professor, Head, Department of Ophthalmology.
Russian Federation
Sergey Yu. Astakhov, MD, PhD, DSc, Professor, Head, Department of Ophthalmology.
Yu. V. Takhtaev
First Pavlov State Medical University of
St. Petersburg.
Russian Federation
Yuri V. Takhtaev, MD, PhD, DSc, Professor, Department of Ophthalmology.
Russian Federation
Yuri V. Takhtaev, MD, PhD, DSc, Professor, Department of Ophthalmology.
S. A. Novikov
First Pavlov State Medical University of
St. Petersburg.
Russian Federation
Sergey A. Novikov, MD, PhD, DSc, Professor, Department of Ophthalmology.
Russian Federation
Sergey A. Novikov, MD, PhD, DSc, Professor, Department of Ophthalmology.
V. A. Turgel
First Pavlov State Medical University of
St. Petersburg.
Vadim A. Turgel, MD, Resident, Department of Ophthalmology.
Vadim A. Turgel, MD, Resident, Department of Ophthalmology.
References
1. Rogers S, McIntosh R, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010;117(2):313-319.
2. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. Journal of Thrombosis and Haemostasis. 2010;8(9):1886-1894.
3. Koizumi H., Ferrara DC., Brue C., Spaide RF. Central vein occlusion case-control study. Am J Ophthalm. 2007; 144: 858-63.
4. Tultseva S.N. The role of hereditory and acquired thrombophilia in the pathogenesis of retinal vein occlusion: extended abstract of dissertation. FSBEI HE «Academician I.P. Pavlov First St Petersburg State Medical University» of the Ministry of Healthcare of the Russia, 2014.
5. O’Mahoney P, Wong D, Ray J. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008;126(5):692-699.
6. Shahsuvaryan M, Melkonyan A. Central retinal vein occlusion risk profile: a case-control study. European Journal of Ophthalmology. 2003;13(5):445-452.
7. Hayerh S, Zimmerman B, McCarthy M, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. American Journal of Ophthalmology. 2001;131(1):62-77.
8. Stem M, Talwar N, Comer G, Stein J. A longitudinal analysis of risk factors associated with central retinal vein occlusion. American Journal of Ophthalmology. 2013;120(2):362-370. doi:10.1016/j.ophtha.2012.07.080.
9. Aghamirsalim M, Sorbi R, Naderian M, Cugati S, Shahsuvaryan M, Hashemi M. Management of retinal vein occlusion, who is responsible? Acta Med Iran. 2016;54(11):731-736.
10. Janssen M, den Heijer M, Cruysberg J, Wollersheim H, Bredie S. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? Throm Haemost. 2005;93:1021-1026.
11. Shin Y, Cho H, Kim J, Bae K, Kang M, Shin J, et al. Prevalence and associated factors of retinal vein occlusion in the Korean National Health and Nutritional Examination Survey, 2008-2012. Medicine. 2016;95(44):1-8.
12. Ponto K, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild P, et al. Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. Journal of Thrombosis and Haemostasis. 2015;13:1254-1263. doi: 10.1111/jth.12982.
13. Rosa A, Ortega K, Decio Mion J, Nakashima Y. Prevalence of arterial hypertension in branch retinal vein occlusion patients. Arg Bras Oftalmol. 2008;71:162-166.
14. Zhou J, Xu L, Wang S, et al. The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology. 2013;120(4):803-808.
15. R Klein; B E Klein; S E Moss; S M Meuer. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol So. 2000;8: 133-143.
16. Yau J, Lee P, Wong T, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. International Medicine Journal. 2008;38:904-910.
17. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. Journal of Ophthalmology. 2014:1-5. doi: 10.1155/2014/724780.
18. Go AS, Mozaffarian D et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):28-292.
19. Drukteinis J, Roman M, Fabsitz R, et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: The Strong Heart Study. Circulation 2006;115(2):221-227
20. Recchia F, Carvalho-Recchia C, Hassan T. Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol. 2004;122:317-321.
21. Balogh Z, Berta A, Pfliegler G, Nagy V. Bilateral central retinal vein occlusion caused by malignant hypertension in a young patient. Clinical and experimental hypertension. 2011;33(1):53-55.
22. Ahluwalia J, Rao S, Varma S, Gupta A, Bose S, Masih J, et al. Thrombophilic risk factors are uncommon in young patients with retinal vein occlusion. Retina, the journal of retinal and vitreous diseases. 2015;35(4):715-719.
23. Lam H, Lahey J, Kearney J, Od R, Lehmer J, Tanaka S. Young patients with branch retinal vein occlusion. Retina, the journal of retinal and vitreous diseases. 2010;30(9):1520-1523.
24. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol. 1993;37(6):393-417
25. Liu Q, Lahey M, Karlen R, Stewart J. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Retina, the journal of retinal and vitreous diseases. 2017;0(0):1-5.
26. Kuhli-Hattenbach C, Scharrer I, Luchtenberg M, Hattenbach L. Coagulation disorders and the risk of retinal vein occlusion. Thrombosis and Haemostasis. 2010;103(2):299-305.
27. Glueck C.J., Hutchins R.K., Jurantee J., Khan Z., Wang P. Thrombophilia and retinal vascular occlusion. Clin Ophthalmol. 2012; 6: 1377–1384
28. Rehak M, Rehak J, Muller M, Faude S, Faude F, Siegemund A, et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Thromb Haemost. 2008;99:925-929.
29. Wittstrom E. Central retina vein occlusion in younger Swedish adults: case reports and review of the literature. The Open Ophthalmology Journal. 2017;11:89-102
30. Hayreh S, Zimmerman M. Branch retinal vein occlusion: natural history of visual outcome. JAMA Ophthalmology. 2014;132(1):13-22.
31. Hayreh S. Prevalent misconceptions about acute retinal vascular occlusive disorders. Progress in Retinal and Eye Research. 2005;24(4):493-519.
32. Nadar SK, Tayebjee MH, Messerli F, Lip GY. Target organ damage in hypertension: pathophysiology and implications for drug therapy. Curr Pharm Des. 2006; 12(13):1581-92.
33. Rubattu S, Pagliaro B, Pierelli G et al. Pathogenesis of target organ damage in hypertension: role of mitochondrialoxidative stress. Int J Mol Sci. 2014 Dec 31;16(1):823-39
34. Schulz E, Wenzel P, Münzel T, Daiber A. Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal. 2014 Jan 10; 20(2):308-24.
35. Redheuil A, Yu WC, Wu CO et al. Reduced ascending aortic strain and distensibility: earliest manifestations of vascular aging in humans. Hypertension. 2010;55(2):319-26
36. O'Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007 Jul 3; 50(1):1-13.
37. Kumar B, Yu DY, Morgan WH, et al. The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology. 1998;105:424–7.
38. Christoffersen NLB, Larson M. Pathophysiology and hemodynamics of BRVO. Ophthalmology. 1999;106:2054–62.
39. Kida T, Flammer J, Oku H, Konieczka K, Morishita S, Horie T, Ikeda T. Vasoactivity of retinal veins: a potential involvement of endothelin-1 (ET-1) in the pathogenesis of retinal vein occlusion (RVO). Experimental Eye Research. 2018;176:207-209.
40. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006;124(5):726-32
41. Capua M, Coppola A, Albisinni R, Tufano A, Guida A, et al. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis. 2010;30:16-22. doi: 10.1007/s11239-009-0388-1.1
42. Ho JD, Liou SW, Lin HC. Retinal vein occlusion and the risk of stroke development: a fi ve-year follow-up study. Am J Ophthalmol. 2009;147:283–90.
43. Rothman A, Thomas A, Khan K, Fekrat S. Central retinal vein occlusion in young individuals. Retina, the journal of retinal and vitreous diseases. 2018;0(0):1-8.
44. Lyamina N.P., Nalivaeva A.V., Senchikhin V.N., Lipchanskaya T.P. MASKED HYPERTENSION IN YOUNG PERSONS: PREVALENCE, SIGNIFICANCE OF CARDIOVASCULAR RISK FACTORS AND PROGNOSIS BY GENDER DIFFERENCES. Russian Journal of Cardiology. 2017;(4):7-12. (In Russ.)
45. Rao V, Ulrich N, Viera A, Parlin A, Fekrat S, Chavala S. Ambulatory blood pressure patterns in patients with retinal vein occlusion. Retina, the journal of retinal and vitreous diseases. 2016;0(0):1-7.
46. Tultseva S.N., Astakhov U.S., Titarenko A.I., Rukhovets A.G. 24-hour blood pressure profile in young and middle-aged patients with retinal vein occlusion. 2017;23(2):122-130 (in Russ)
47. Park S, Moon S, Lim S, Yoon I, Choi K, Lee H. Diurnal blood pressure variation in the retinal vein occlusion. J Korean Ophthalmol Soc. 2013;54(9):1371-1378.
48. Pesin N, Mandelcorn E, Felfeli T, Ogilvie R, Brent M. The role of occult hypertension in retinal vein occlusions and diabetic retinopathy. Canadian Ophthalmology Society. 2017;52(1):31-33.
49. Tanano I, Nagaoka T, Sogawa K et al. Impaired systemic vascular endothelial function in patients with branch retinal vein occlusion. Current Eye Research. 2013;38(1):114-118.
50. Hollo G. Plasma endothelial-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol. 1999;83:127-128.
51. Flammer J, Konieczka K. Retinal venous pressure: the role of endothelin. The EPMA Journal. 2015;6:1-12.
52. Martinez F, Furio E, Fabia M, Perez A, Gonzalez-Albert V, Rojo-Martinez G, et al. Risk factors associated with retinal vein occlusion. Int J Clin Pract. 2014;68(7):871-881. doi: 10.1111/ijcp.12390.
53. Recchia FM, Carvalho-Recchia CA, Hassan TS. Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol. 2004;122:317–21
54. Kuo J, Lai C, Ong F, Shih C, Yeung L, Chen U, et al. Central retinal vein occlusion in a young Chinese population. Retina. 2010;30(3):479-484. doi: 10.1097/IAE.0b013e3181b9b3a0.
55. Kuhli-Hattenbach C, Miesbach W, Luchtenberg M, Kohnen T, Hattenbach L. Elevated lipoprotein (a) levels are an independent risk factor for retinal vein occlusion. Acta Ophthalmica. 2016. doi: 10.111/aos.13228.
56. Tultseva S.N. Thrombophilia as a risk factor of central retinal thrombosis development among young people. Ophthalmologicheskie vedomosti. 2008; 1(1): 46-51 (In Russ)
57. Rehak M, Krcova V, Slavik L, Fric E, Langova K, Ulehlova J, et al. The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. Can J Ophthalmol. 2010;45(2):171-175.
58. Karska-Basta I, Kubicka-Trzaska A. Thrombophilia - a risk factor of retinal vein occlusion? Klin Oczna. 2013;115(1):29-33
59. Glueck CJ, Wang P, Hutchins R et al. Ocular vascular thrombotic events: central retinal veinandcentralretinalarteryocclusions. ClinicalandApplied Thrombosis/Hemostasis,2008, vol.14,no.3,pp.286-294
60. Kuhli C, Hattenbach LO, Scharrer I, Koch F, Ohrloff C. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:163-168.
61. Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y. Systemic abnormalities associated with retinal vein occlusion in young patients. Clinical Ophthalmology. 2017;11:441-447.
62. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitaminB12, and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003;136:1136–50
63. Gopinath B, Wang JJ, Flood VM, Burlutsky G, Wong TY, Mitchell P. The associations between blood levels of homocysteine, folate, vitamin B12, and retinal vascular caliber. Am J Ophthalmol. 2009;148:902–9.
64. Narayanasamy A, Subramaniam B, Karunakaran C, Ranganathan P, Sivaramakrishnan R, Sharma T, Badrinath VS, Roy J. Hyperhomocysteinemia and low methionine stress are risk factors for central retinal venous occlusions in an Indian population. Invest Ophthalmol Vis Sci. 2007;48:1441–6.
65. Li D, Zhou M, Peng X, Sun H. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis. BMC Ophthalmology. 2014;14:147.
66. Sottilotta G, Siboni SM, Latella C, Oriana V, Romeo E, Santoro R, et al. Hyperhomocystinemia and C677T MTHFR genotype in patients with retinal vein thrombosis. Clin Appl Thromb Hemost. 2010;16:549-553.
67. Devi S, Suganeswari G, Sharma T, Thennarasu M, Anayarkanni N. Homocysteine induces oxidative stress in young adult central retinal vein occlusion. Br J Ophthalmol. 2012;96:1122-1126. doi: 10.1136/bjophthalmol-2011-301370.
68. Wadani F, Khandekar R, Salim G, Ali M, Ramzi S. Hyperhomocysteinia is a risk for retinal venous occlusion: A case control study.
69. Salaun N, Delyfer MN, Rougier MB, Korobelnik JF. Assessment of risk factors for retinal vein occlusions in patients under 60 years of age. J Fr Ophthalmol. 2017;30(9):918-923.
70. Napal J, Neila S, Perez-Montes R, Sierra I, Ruiz S, Hernandez J. The role of coagulation disorders in patients with retinal vein occlusion. QJM. 2016;109(2):97-102. doi: 10.1093/qjmed/hcv088.
71. Sartori M, Barbar S, Dona A, Piermarocchi S, Pilotto E, Saggiorato G, et al. Risk factors antithrombotic treatment and outcome in retinal vein occlusion: an age-related prospective cohort study. Clin Ophthalmol. 2012;6:1377-1384.
72. Sartori M, Barbar S, Dona A, Piermarocchi S, Pilotto E, Saggiorato G, et al. Risk factors antithrombotic treatment and outcome in retinal vein occlusion: an age-related prospective cohort study. Clin Ophthalmol. 2012;6:1377-1384.
73. Sottilotta G, Orina V, Latella C, Luise F, Piromalli A, Ramirez F, et al. Role of hyperhomocystinemia in retinal vascular occlusive disease. Clin Appl Thromb Hemost. 2007;13:104-107.
74. Sofi F, Rossella M et al. Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis. 2008, 198(1): 223-227
75. Vine AK. Investigation of patients with retinal arterial or venous occlusive disease. Compr Ophthalmol Update. 2003;4:193–9
76. Bashshur Z, Taher A, Masri A, Najjar D, Arayssi T, Noureddin B. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors. Retina, the journal of retinal and vitreous diseases. 2003;23(4):486-490.
77. Carbone J, Sanchez-Ramon S, Cobo-Soriano R, Seoane E, Aparicio MJ, Ruiz-Tiscar JL. Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders. Comparison with inflammatory diseases. J Rheumatol. 2001;28:2437-2441.
78. Werther W, Chu L, Holekamp N, Do D, Rubio R. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol. 2011;122(3):326-331.
79. Li M., Xiaolan H., Huang J., Tan Y., Yang B. et al. Impact of retinal vein occlusion on stroke incidence: a meta-analysis. J Am Heart Assoc. 2016:5(12)
Review
For citations:
Astakhov, Yu.S., Titarenko A.I., Tultseva S.N., Astakhov S.Yu., Takhtaev Yu.V., Novikov S.A., Turgel V.A. Systemic risk factors for retinal vein occlusion in young and middle-aged patients. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2018;24(6):666-673. (In Russ.) https://doi.org/10.18705/1607-419X-2018-24-6-666-673
Views:
1423
Email this article 